France: Macron does not want to move forward with medicinal cannabis in 2024

In a surprising turn of events, the French government, led by President Emmanuel Macron, has decided not to propose the legalization of cannabis for medicinal use in 2024. Despite overwhelming public support, particularly from patients who participated in a pilot project, Macron's government appears to be halting what could have been a promising change for the country's healthcare landscape.

To date, the distribution of medicinal cannabis in France is confined to a trial period involving 2.000 patients, suffering from diseases such as epilepsy, cancer, neuropathic pain, palliative care and spasticity. These patients have had limited access to cannabis-based medicines. The project aimed to evaluate the effectiveness and legality of such treatments, with products available in selected pharmacies.

Public and medical opinion contrasts with that of the government

Reports indicate that around 91% of patients involved in the trial are in favor of general legalization. Patients reported significant improvements, especially in symptom management, particularly pain relief and palliative care. However, despite the feedback positive and clear benefits, the French government seems hesitant to expand access.

Although patients and health professionals have mobilized for the integration of cannabis for medicinal purposes into common law, opposition from groups such as the Interministerial Mission to Fight Drugs and Addictive Behaviors (MILDECA) has impeded progress. Critics argue that these forces are driven by political considerations rather than the well-being of the patients who stand to benefit from them.

Prominent figures in the medical community, such as Professor Nicolas Authier, chairman of the Scientific Committee for Medicinal Cannabis, have expressed their concerns. They highlight the need for a comprehensive approach that prioritizes the well-being of patients over ideological opposition. Experts call on the government to take into account the substantial positive impact observed during the trial period, highlighting that thousands of chronically ill people are eagerly awaiting relief.

The future of cannabis for medicinal purposes in France

With the ongoing pilot project ending in March 2024, the fate of medicinal cannabis in France is suspended, with two possible scenarios on the horizon:

1. Extending the experience: The project could be expanded to continue supporting existing patients, ensuring they receive the necessary medicines. However, no new patients would be enrolled, leaving countless others without access.
2. Complete termination: Alternatively, the trial may end abruptly, leaving patients without any access to cannabis-based medicines. Unless alternative solutions are found through changes, this scenario appears dire for those who need it.

A ray of hope

Despite the current setbacks, there is still a glimmer of hope. Discussions surrounding the Social Security Financing Bill (PLFSS) 2024 could provide an opportunity for the legalization of cannabis for medicinal purposes. Changes may be proposed, either by the government or through collaborative efforts with influential figures such as Caroline Janvier, a member of the French National Assembly.

The path to legalizing cannabis for medicinal purposes in France appears to be full of obstacles. Although patients and legalization advocates remain hopeful, the government's position raises concerns about the future of healthcare in the country. As the debate continues, the fate of thousands of suffering individuals is left hanging, awaiting a decision that could have a significant impact on their quality of life.